Abstract: Metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors and are densely expressed in medium spiny projection neurons of striatum. Emerging evidence demonstrates a significant role of mGluRs in the regulation of striatal functions. Activation of mGluRs alters local transmitter release and behaviors of experimental animals. In particular, mGluRs regulate phosphorylation of several key signaling proteins (protein kinases and transcription factors) resulting in significant changes in immediate early gene and neuropeptide gene expression in striatal neurons. The prominent involvement of mGluRs in genomic responses to synaptic stimulation is considered to play a pivotal role in the development of synaptic/neuronal plasticity underlying long-term adaptive changes in cellular physiology related to a variety of neurologic disorders. Available data indicate that the eight subtypes of mGluRs have distinct effects on gene expression. The group I subtypes (mGluR1/5) facilitate, whereas group II (mGluR2/3) and III (mGluR4/6/7/8) subtypes inhibit, gene expression. Due to their significance in regulating drug action, mGluRs have been considered as promising targets for the development of novel therapeutic drugs for the treatment of drug addiction. The present review summarizes the roles of mGluRs in the regulation of behavior, transmitter release and particularly genomic responses in striatal neurons to dopamine stimulation, following a description of anatomical organization of mGluRs in the striatum. The possible pre-and postsynaptic mechanisms that process mGluR modulatory effects are also discussed in detail. Finally, potential of mGluRs as targets for the development of therapeutic drugs for addictive and other mental illnesses concludes this review.
INTRODUCTION
As a major excitatory neurotransmitter in the central nervous system, glutamate is involved in the regulation of a variety of neural functions. Through interacting with specific glutamate receptors, glutamate controls normal cellular activity and cellular responses to extracellular stimulation. There are two major families of glutamate receptors: ionotropic (ligand-gated ion channels) and metabotropic (Gprotein coupled) receptors based on their biochemical, pharmacological, and molecular profiles [1] . Compared to thoroughly investigated roles of the ionotropic receptors, the physiological participation of metabotropic glutamate receptors (mGluRs) in overall neural activity is poorly elucidated and remains to be a prime theme in recent glutamate studies. At present, eight subtypes of mGluRs (mGluR1-8) have been molecularly characterized from rat brain tissues. Like ionotropic receptors, mGluR subtypes are heterogeneous in their distribution, pharmacology, signaling linkages, and ultimately physiology. Based on their genomic homology, pharmacology and primarily intracellular responses to activation of the transgenic mGluRs in Xenopus oocyte, the eight subtypes can be classified into three *Address correspondence to this author at the Department of Pharmacology, University of Missouri-Kansas City, School of Pharmacy, 2411 Holmes Street, Rm. M3-225, USA; Tel: 816 235-1786; Fax: 816 235-1776; E-mail: wangjq@umkc.edu functional groups [2] . Group I mGluRs consist of mGluR1/5 subtypes. Pharmacological activation of this group of mGluRs increases phosphoinositide (PI) hydrolysis, resulting in the subsequent Ca 2+ release from internal stores and protein kinase C (PKC) activation. The main signaling pathway which group II (mGluR2/3) and III (mGluR4/6/7/8) mGluRs are linked to is adenylyl cyclase and cAMP formation. Activation of those two groups of mGluRs leads to inhibited adenylate cyclase and reduced cAMP levels. The linkages to the intracellular effectors listed above and also others allow mGluRs to preferentially involve in the relatively slower effects in intracellular and intranuclear compartments, such as DNA transcription (gene expression), as opposed to rapid signal transmission in synapses primarily mediated by the ionotropic receptors.
As a major structure in the basal ganglia, the dorsal (caudoputamen) and ventral (nucleus accumbens) striatum regulates extrapyramidal motor behaviors and behaviors unrelated to movement, i.e., cognitive behaviors (learning and memory, affection, addiction, rewarding, reinforcement, etc.). During the last decade, the striatum has been the focus of experimental animal studies on brain mechanisms underlying addictive plasticity of drugs of abuse. It was established that increased release of dopamine from mesolimbic and mesostriatal pathways initiates changes in locomotor behaviors following administration of the psychostimulants, cocaine and amphetamine. Molecular studies further reveal that these dopamine stimulants alter gene expression in striatal medium-sized spiny neurons which project to the substantia nigra (striatonigral neurons) or pallidum (striatopallidal neurons). A large number of sets of genes respond to drug stimulation. Among them, the immediate early genes (IEG), c-fos and zif/268, and several neuropeptide genes, preprodynorphin (PPD), substance P and preproenkephalin (PPE), have been investigated most extensively. Alterations in expression of these genes are thought to initiate adaptive changes in cellular physiology (neuroplasticity) related to addictive properties of substance abuse [3, 4] .
Although dopamine transmission has been documented as an important mediator of inducible gene expression in the striatum, increasing evidence suggests an equally important role of glutamate system in drug action [5] [6] [7] [8] [9] . This notion is based on the facts that the striatum is innervated with abundant glutamatergic projections from widespread areas of forebrain and glutamate receptors are densely expressed in the striatum both pre-and postsynaptically. Available data from functional studies show that pharmacological and genetic manipulations of mGluR activity alter local transmitter release and behaviors in normal and drug-treated animals [10] [11] [12] [13] . In particular, activation of mGluRs seems to be essential for cocaine-and amphetamine-regulated gene expression imperative for striatal plasticity [7] . As a powerful modulator of psychostimulant effects, mGluRs are therefore considered to be promising targets for the development of novel therapeutic agents for neurologic disorders derived from abused drugs.
This review summarizes recent anatomical data regarding subsynaptic and subcellular distribution of mGluRs in striatal area. The role of mGluRs in the regulation of behavioral activity and transmitter release in the striatum is then reviewed. A particular attention is given to genomic responses of striatal projection neurons to dopamine stimulation. The possible pre-and postsynaptic mechanisms and intracellular signaling pathways that underlie mGluRregulated cellular and genomic activities are discussed in detail. Finally, a possible potential of mGluRs as targets for the development of therapeutic drugs for addiction treatment concludes this review.
SUBSYNAPTIC AND SUBCELLULAR LOCALI-ZATION OF mGluRs IN THE STRIATUM
Subsynaptic and subcellular localization determines functional roles that mGluRs may play. Through almost a decade of efforts, basic knowledge of mGluR distribution in striatal area has been obtained, although often times it is still inadequate when considering a specific function for a specific subtype in a specific phenotype of cells or terminals. A large number of studies using different histological techniques reveal that the striatum represents one of subcortical areas where mGluRs are densely distributed both pre-and postsynaptically. Quantitative receptor autoradiography reveals high levels of mGluR binding site in striatal region [14] . Since lesions of corticostriatal projections had a little effect on mGluR binding quantity, 90% of mGluRs are thought to locate on postsynaptic striatal neurons [15] .
Studies with in situ hybridization [16] [17] [18] [19] and immunohistochemistry [20] [21] [22] show the presence of mGluR1-5 and mGluR7 in rat striatal projection neurons with high levels of mGluR3/5/7 and low to moderate levels of mGluR1/2/4 [19, 23, 24] . MGluR1/3/5/7 receptors are colocalized with the vast majority (60% to 70%) of either striatonigral neurons or striatopallidal neurons [25] [26] [27] [28] . Interestingly, there seemingly exists an mGluR1/5 segregation between two major projection neurons: mGluR1 is primarily present in striatonigral neurons whereas mGluR5 in striatopallidal neurons [25, 27] . In addition to projection neurons, at least mGluR1/2/5 subtypes are expressed in a small population of large polygonal neurons, likely cholinergic interneurons [19, 24, [29] [30] [31] . With lesions or double immunofluorescent labeling with presynaptic terminal markers, mGluR2/3/4/7 subtypes are found to present on incoming glutamatergic and/or dopaminergic terminals [24, 28, [32] [33] [34] . Although it is not yet conclusive, group I mGluRs are seemingly concentrated in an annulus surrounding the edge of the postsynaptic density (perisynaptic sites), whereas group II/III mGluRs are both pre-and postsynaptic in the striatum [34] [35] [36] . The subtypes within group I and group III mGluRs share similar ultrastructural localization relatively close to transmitter release sites whereas group II subtypes have no close association with synapses [34] . Unlike the ionotropic glutamate receptors that are associated with somata and dendrites, mGluR subtypes except for mGluR4 seem to be preferentially associated with fibers rather than neuronal cell bodies [35, 37] . Future morphological studies are needed to further characterize (1) subsynaptic (pre-vs. postsynaptic) and subcellular (somata, dendrites and axons) localization of mGluRs, (2) localization of mGluRs on specific phenotype of striatal neurons or incoming terminals, (3) co-localization of mGluRs with other receptors of interest, and (4) subtypespecific localizations. Fine characterizations of those themes are prerequisite for evaluating which subtype of mGluRs on which phenotype of intrinsic neurons or extrinsic terminals is involved in which function.
There are dense innervations of glutamatergic projections in the striatum that use glutamate as a releasing transmitter [38] . From widespread areas of cerebral cortex and thalamus, glutamatergic afferents converge to the entire dorsal striatum. The areas that send glutamatergic projections to the ventral striatum include several key areas in the basal ganglia: the amygdala, thalamus, ventral subiculum, hippocampus and prefrontal cortex. Extrinsic glutamatergic terminals make asymmetrical (excitatory in nature) synaptic contacts with intrinsic striatal neurons, including medium-sized spiny projection neurons [39] [40] [41] [42] and aspiny interneurons (GABAergic or cholinergic neurons) [43, 44] . Since the projection neurons are also major synaptic targets of dopaminergic terminals from the midbrain [45, 46] , functional activity of a single striatal projection neuron can be modulated postsynaptically by both glutamate and dopamine inputs. Further evidence supporting this is that glutamatergic and dopaminergic terminals are found to directly converge on the dendritic spines of the same striatal output neurons [41, 47] . In sharp contrast to popular synapses between extrinsic terminals and intrinsic neurons, axoaxonic synapses between the two major incoming terminals are hardly visible throughout the entire striatum [41,45,47-49].
This restricts the possibility of presynaptic interactions between glutamate and dopamine terminals in a classic synaptic fashion. However, effective interactions between the two terminals can still take place through non-traditional synaptic contacts [41, 49] . Through diffusion of transmitter away from the synapse where it is released, dopamine terminal characters can be modified presynaptically by diffused glutamate via an extrasynaptic heteroreceptor mechanism, and vice versa.
REGULATION OF BEHAVIOR BY mGluRs
Experimental studies on physiological roles of striatal mGluRs started with behavioral investigation. With nonsubgroup selective agonists/antagonists first available in the early 90's, mGluR functions in regulating spontaneous behaviors were evaluated in a non-subgroup fashion. Unlike the ionotropic glutamate receptor agonists that cause controversial effects on motor activity when injected into the striatum, the mGluR agonists seem to consistently induce stimulation of spontaneous activity. First reports from Schoepp's group in 1991 [50] and 1992 [51] described in rats that an acute injection of a non-subgroup selective mGluR agonist, (1S,3R)-1-aminocyclopentane-1,3-dicar-boxylic acid (ACPD), into the unilateral dorsal striatum at a fairly high dose range (500 -2000 nmol) caused rotation contralateral to the injection side, an indication of enhanced striatal neuronal activity in the injected side. Similar findings were generally repeated afterwards in other laboratories [52] [53] [54] [55] . Since these behavioral changes were blocked by a non-subgroup selective mGluR antagonist, (+)-α-methyl-4-carboxyphenyl-glycine (MCPG), but not by the ionotropic glutamate receptor antagonists, selective activation of mGluRs is believed to mediate the ACPD effect. Increased locomotion was also observed after bilateral ACPD injection into the nucleus accumbens [56, 57] . These early findings uncover a stimulative effect of striatal mGluRs on basal motor activity.
Rapid progress of developing subgroup-specific agents following the first generation of non-subgroup drugs has made possible to define subgroup-specific roles of mGluRs in behavioral modulation in recent years [58] . Using the agonists with confirmed selectivity and effectiveness in vivo, several studies conducted in this laboratory and others have indicated that behavioral stimulation by ACPD is mediated via selective activation of group I mGluRs rather than group II/III receptors. Infusion of a selective group I agonist, 3,5-dihydroxyphenylglycine (DHPG), into either the dorsal or the ventral striatum at moderate doses (20 to 80 nmol) induced hyperlocomotion and characteristic stereotypical behaviors [59, 60] . Such behavioral responses were sensitive to a group I selective antagonist, n-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide (PHCCC), but not to a group II/III selective antagonist, (RS)-α-methylserine-Ophosphate monophenyl ester (MSOPPE) [60] [66] [67] [68] . Intraaccumbens administration of the group I antagonists, S-4-CPG or (R,S)-1-aminoindan-1,5-dicarboxylic acid (AIDA), also had no behavioral effects [69, 70] . Thus, as far as normal behavior is concerned, group I mGluRs are not significant in maintaining spontaneous behavioral activity.
In addition to dopamine receptors (both D1 and D2) responsible for behavioral stimulation induced by dopamine stimulants, several studies in recent years implicate mGluRs in the modulation of acute cocaine-and amphetaminestimulated motor behaviors in a subgroup-specific fashion. Pharmacological activation or blockade of local group I mGluRs with intrastriatal injection of the respective agonist and antagonist had a minimal effect on acute amphetaminestimulated behaviors [70] . Similarly, systemic injection of the mGluR5 antagonist MPEP did not significantly affect acute cocaine-and amphetamine-stimulated locomotion (68, Parelkar and Wang, unpublished observations). These results seem to indicate that group I mechanism is not significantly involved in acute behavioral effects of stimulants, even though group I receptors themselves upon stimulation can increase motor activity. Two recent pharmacological studies on mutant mice reveal some interesting data. In mGluR1 knockout mice, the overall motor responses to acute amphetamine or D1 agonist stimulation were found to be significantly greater as compared to wild-type mice [71, 72] .
This indicates an mGluR1-specific negative feedback mechanism controlling dopamine stimulation of motor activity, which may be resulted from mGluR1-regulated gene expression (see below).
The group II-specific regulation of acute motor action of stimulants was recently evaluated in rats in this laboratory and others. We found a significant attenuation of amphetamine-evoked locomotion and rearing following injection of the group II agonist DCG-IV into the dorsal striatum (Fig.  1A) [62]. Systemic injection of another group II agonist LY379268 produced the same result [73] . These data seem to support an inhibitory role of group II mGluRs in the evoked motor activity by dopamine stimulants. However, there are controversial reports showing that the group II agonist, (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC), potentiated the locomotor response to the partial D1 agonist SKF 38393 [74] and the group II antagonist, (2S)-alphaethylglutamic acid (EGLU), when injected into the nucleus accumbens attenuated amphetamine-evoked motor activities [70] . Those disputing data may reflect differences in experimental conditions among those studies, especially selectivity and potency of those different group II agents used.
Behavioral studies on group III receptors yielded more consistent data. Intracaudate injection of a group III agonist (L-AP4) blocked hyperlocomotion induced by cocaine, amphetamine, or apomorphine (Fig. 1B) , and the blocking effect of L-AP4 was sensitive to a group III selective antagonist, α-methyl-4-phosphonophenylglycine (MPPG) [63] . Intra-accumbens injection of L-AP4 mimicked the same blocking effect on the behavioral response to the D1 agonist [75] . The group III agonists have also found to produce anticonvulsive and anti-epileptogenic effects in rats and mice [76] [77] [78] [79] . It is interesting to note that the behavioral activity induced by cocaine was much more sensitive to L-AP4 than that induced by amphetamine [63] . At 100 nmol, L-AP4 completely blocked cocaine effect whereas amphetamine-and apomorphine-stimulated behaviors were blocked to a smaller extent (Fig. 1B) . The mechanism responsible for different susceptibility of these stimulants to L-AP4 blockade is unclear, but may be related to their distinctive terminal characteristics resulting in the enhancement of extracellular dopamine levels [80, 81] .
As compared to the acute motor regulation, mGluRs' roles in regulating chronic behavioral perspectives could be more important for and relevant to their contributions to addictive plasticity. The mGluR-regulated relatively slower intracelluar responses may contribute to the development of plasticity related to long-lasting behavioral changes induced by repeated drug exposures. Indeed, MCPG injected into the ventral tegmental area blocked the induction of amphetamine sensitization [82] . One recent report from Conquet's laboratory shows that mice lacking the mGluR5 gene did not self-administer cocaine, a loss of reinforcing effect of cocaine [83] . Moreover, mGluR receptor gene expression is subject to be altered in response to repeated dopamine stimulation [84, 85] . An increase in mGluR1 and a decrease in mGluR5 mRNA levels were found in the striatum of rats that developed behavioral sensitization to repeated amphetamine administration [84] . The altered gene expression may substrate changes in receptor functions important for initiation and/or expression of sensitization. Apparently, the study on the roles of mGluRs in processing chronic behavioral changes is still at its infant stage, and remains as a promising avenue for future elucidation of receptor mechanisms underlying drug abuse.
REGULATION OF TRANSMITTER RELEASE BY mGluRs
Given proven presynaptic distribution of mGluRs, especially group II/III subtypes, on incoming terminals, mGluRs are considered to exert a significant modulation of both basal and phasic release of major transmitters in the striatum [11, 12] . The modulation could involve the regulation of glutamate release via an autoreceptor mechanism, as well as dopamine and other transmitter release via a heteroreceptor mechanism. Early studies using in vivo microdialysis in freely moving rats reveal that mGluR stimulation with ACPD (usually in the mM range through the probe) increased basal dopamine levels in the rat striatum [86] [87] [88] [89] [90] . High concentrations of ACPD were also effective in elevating basal glutamate levels in the striatum and in most cases caused behavioral stimulation and/or convulsion [91] . However, in contrast to the facilitatory effect on basal dopamine/glutamate release, mGluRs exert an inhibitory influence on phasic transmitter release. This is demonstrated by the finding that ACPD reduced dopamine release evoked by a high concentration of KCl [86] and glutamate release induced by electrical stimulation of corticostriatal neurons [92] . Those studies suggest that during normal conditions mGluR activation facilitates basal dopamine and glutamate release whereas, during conditions of hyperstimulation in which massive transmitters are released, mGluR activation attempts to reduce excessive transmitter release. Those opposite modulatory effects may be due to different subgroups of mGluRs worked under different conditions.
Using the subgroup-selective agents, recent microdialysis studies demonstrate a subgroup-specific modulation of transmitter release. Group I mGluRs seem to modulate basal dopamine and glutamate release in a facilitatory fashion. Perfusion of the group I agonist DHPG or mGluR5 agonist (RS)-2-chloro-5-hydroxy-phenylglycine (CHPG) significantly increased dopamine or glutamate extracellular levels with respect to basal values [88, [93] [94] [95] [96] . The increased dopamine/glutamate release was prevented by the group I or mGluR5 antagonists [93] . Given the lack of anatomically proven evidence of presynaptically located group I receptors in striatal area, the group I regulation of transmitter release may largely mediated by transsynaptic (polysynaptic) or intercellular mechanisms. The group II agonists including DCG-IV, APDC, and (2S,3S,4S)-α-carboxycyclopropylglycine (L-CCG-I) exert an inhibitory influence on basal dopamine and glutamate release when administered in a physiological dose range ( [97] [98] [99] [100] , but 88). Moreover, inhibitory group II receptors are tonically active in inhibiting transmitter release from both corticostriatal and mesostriatal terminals since blockade of group II receptors resulted in increased dopamine and glutamate release [97] [98] [99] . The group II-mediated modulation likely involves both vesicular and nonvesicular terminal characteristics, because altered glutamate release by the agonist or antagonist was prevented by the N-type Ca 2+ channel inhibitor and the glutamate release evoked by KCl depolarization was antagonized by APDC [97] . Like group II receptors, significant in vivo glutamatergic tone exists on striatal group III mGluRs to suppress extracellular dopamine levels [97, 101] . One study also shows that presynaptic group I and II mGluRs oppositely modulate striatal acetylcholine release since the facilitation and inhibition of KCl-induced acetylcholine release were induced after administration of the group I and II agonists, respectively [102] .
A few reports have documented the roles of mGluRs in regulating the striatal dopamine overflow stimulated by dopamine stimulants. Darracq and co-workers show that MCPG reduced the dopamine release in the rat nucleus accumbens and hyperlocomotion evoked by acute local and systemic amphetamine treatments [103] . They suggest that the activation of accumbens mGluRs is required for functional dopamine release following amphetamine injection. However, this study suggests a mediating or depending role of mGluRs in the stimulated dopamine release. It is then difficult to fit this role into any specific subgroup of mGluRs because mGluR1 or 5 knockout did not affect dopamine release evoked by cocaine [83] and group II/III receptors are inhibitory in nature. The enhanced group III glutamatergic transmission indeed exerts a potent inhibition of the dopamine release evoked by amphetamine as revealed by a recent study conducted in this laboratory [101] . It was found in this study that pharmacological activation of group III receptors with L-AP4 reduced the dopamine release induced by local perfusion of amphetamine (Fig. 2) . The inhibition of the evoked dopamine release may at least in part contribute to the L-AP4 suppression of amphetamine-stimulated motor activity [63] . However, the terminal characteristics of dopamine release underlying the L-AP4 and amphetamine interaction are somewhat vague. Amphetamine stimulates dopamine release believingly via a Ca 2+ -independent mechanism [81, 104] . It is then unclear how adenylate cyclase-coupled group III receptors are significantly involved in the terminal action of amphetamine. Perhaps, group III receptors could suppress the evoked dopamine release by inhibiting the evoked glutamate release that is essential for stimulants to evoke dopamine release (see below). In addition, the amphetamine-evoked dopamine release was recently found to be partially Ca 2+ -dependent [105] . Accordingly, the group III agonist may operate cAMP/Ca 2+ signaling interactions [106] to suppress the amphetamine effect on dopamine release. Finally, two reports describe an augmented dopamine release in methamphetamine-sensitized rats through a group I and II mGluR-mediated mechanism [107, 108] . More studies are needed to evaluate the mGluR-regulated transmitter release in animals sensitized or addicted to repeated drug administration.
It is worth mentioning dopamine and glutamate balance during the mGluR regulation of releasibility of these two transmitters. While glutamate could exert the dual regulation of dopamine release as discussed above, dopamine could also facilitate or inhibit glutamate release by activating different subtypes of dopamine receptors. Dopamine D2 receptor activation was shown to inhibit striatal glutamate release [109, 110] . In contrast, systemic or local infusion of the direct or indirect dopamine receptor agonists increased glutamate release most likely via a D1 mechanism [105, [111] [112] [113] . Apparently, the two major transmitters in the striatum are capable of controlling each other's release to sophisticatedly coordinate their inputs to postsynaptic neurons. MGluRs may play a central role in the subtle adjustment of synaptic levels of the two transmitters under normal and stimulated conditions. Accumulating data from electrophysiological studies on striatal slices or isolated striatal neurons are in particularly good accordance with the results from in vivo microdialysis detection of transmitter release. Lovinger in 1991 and Calabresi et al. in 1992 reported a decreased glutamate synaptic transmission in the corticostriatal synapses in the presence of ACPD [114; 115] . The decreased transmission appears to result from a presynaptic inhibition as evidenced by the observations that: [1] ACPD decreased the amplitude of excitatory postsynaptic potentials (EPSPs) mediated by either AMPA or NMDA receptors, but did not block responses to agonist application, and [2] ACPD decreased the transmission in the absence of changes in postsynaptic cell properties. Further studies demonstrate that presynaptic depression of corticostriatal synapses can be induced by selective activation of group II or III receptors with the group II receptor agonist DCG-IV or L-CCG-I [116] or the group III agonist L-AP4 or L-serine-O-phosphate (L-SOP) [117] . The group I agonist DHPG did not depress transmission [118] . Thus, the depression is considered to be preferentially mediated by presynaptically located group II/III receptors. Moreover, the group II/III-mediated inhibition of glutamate release reflects the depressed glutamatergic transmission after activation of group II/III receptors.
Several electrophysiological reports described the role of mGluRs in the formation of synaptic plasticity in striatal excitatory synaptic transmission in response to glutamate stimulation [64, 119, 120] . In rat striatal slices containing corticostriatal synapses, high-frequency stimulation induced long-term depression of synaptic transmission, a form of synaptic plasticity [64, 119] . The induced LTD was prevented by the mGluR1 selective antagonist CPCCOet, AIDA, or LY367385 [64, 119] as well as the mGluR5 antagonist MPEP (but not 64). The group II mGluR antagonist LY307452 did not block the LTD. None of the antagonists had any effect on basal synaptic transmission at the concentration used. These results indicate that the two group I mGluR subtypes contribute to the induction of LTD at corticostriatal synapses. Interestingly, although the group II antagonist did not block the LTD induced by high-frequency stimulation, the group II agonist LY354740 itself when exogenously administered induced LTD in cortex-nucleus accumbens synapses [120] . Thus, group II mGluRs also play a role in the control of synaptic plasticity at corticostriatal synapses.
REGULATION OF CONSTITUTIVE GENE EXPRES-SION BY mGluRs
A particularly important role that mGluRs may play is the modulation of intracellular metabotropic activity leading to inducible and functional gene expression. Bridged by multiple second messenger systems, mGluRs may be linked to a signaling cascade controlling transcription rate of target DNAs, a biochemical process called stimulus-transcription coupling. The genomic responses regulated by mGluRs can serve as an integral component of the molecular and cellular mechanisms underlying synaptic and/or cellular plasticity. Thus, elucidation of mGluRs' roles in the regulation of basal and induced gene expression is of significance for understanding the formation of striatal plasticity related to a variety of neurologic disorders, including drug addiction.
Immediate early genes (IEGs) have been prime targets during the last decade for the exploration of receptorregulated gene expression because they are readily inducible in response to various physiological and pharmacological stimuli and can therefore be generally considered to be a functional marker of cellular activity [121] . The first experiment that documents the mGluRs regulation of striatal IEG expression was carried out in primary cultures of rat striatal neurons using Northern blot [122] . In that study, enhanced mGluR activity by ACPD perfusion elevated basal levels of IEG c-fos mRNA, indicating a positive linkage between mGluRs and constitutive c-fos gene expression. A recent in vivo study performed in this laboratory establishes an excellent similarity using quantitative in situ hybridization [123] . Striatal mGluRs stimulation by local ACPD injection elevated c-fos as well as another IEG zif/268 mRNA expression in the rat striatum, which was sensitive to MCPG, but not to the antagonists for NMDA (CPP) or dopamine D1 receptors (SCH-23390). The induction of the two mRNAs was rapid and transient as their increases became evident as early as 30 min, reached a peak at 1 h, and returned to normal levels 3 (c-fos) or 6 (zif/268) h, after ACPD injection. According to this time course, Fos protein induction in the striatum in response to intrastriatal ACPD or DHPG injection was very minimal when immunohistochemical detection was performed > 4 h after drug injection [53, 54] . Nevertheless, the above data confirm an existence of the positive stimulus-transcription coupling between mGluRs and IEG expression in striatal neurons.
One of the most noticeable IEG roles in mature neurons is to exercise as a third messenger in a stimulus-transcription cascade to initiate the so called late-response gene expression [124] . In this scenario, IEGs are rapidly induced via their own stimulus-transcription coupling mechanisms. Induced IEGs in turn function as powerful transcription factors to regulate expression of many other genes, which usually lasts longer and is more likely to directly contribute to longlasting alterations in cellular physiology.
Among a large number of late-response genes, opioid peptide genes, such as PPD and PPE contained by striatonigral and striatopallidal neurons respectively, were examined in connection to mGluR activity. Acute injection of ACPD into the dorsal striatum dose-dependently elevated striatonigral PPD and striatopallidal PPE mRNA levels in the rat striatum in vivo [125] . The increase in opioid peptide mRNA expression was blocked by MCPG. Thus, striatal opioid peptide expression, like the two IEG induction, is also positively linked to mGluR activation. Moreover, compared to the rapid and transient c-fos and zif/268 induction, neuropeptide induction shows a more delayed and prolonged dynamic pattern, as it was evident 2 or 3 h, and lasted more than 10 h, after ACPD injection [125] . The temporal pattern of IEG and opioid induction appears to indicate that the early induced IEG transcription factors trigger, although may not maintain, the subsequent opioid induction. In support of this, intracaudate injection of c-fos antisense oligonucleotides, which knocked down Fos protein quantity, reduced dynorphin-like immunoreactivity induced by dopamine stimulation [126] .
The regulation of neuropeptide mRNA expression by mGluRs is believed to be a subgroup-specific event. Group I receptors may be the receptors that can facilitate gene expression. This is supported by 1) the group I agonist DHPG is more potent than ACPD in inducing PPD and PPE mRNA expression in the striatum [127] , and 2) the group I antagonist PHCCC which itself alone had no effect on the two mRNA levels attenuated DHPG-and ACPDstimulated PPD/PPE expression [127] . As compared to stimulative group I receptors, group II/III receptors may be negatively linked to gene expression according to their negative linkage to the powerful gene stimulator cAMP. However, this notion remains to be proven experimentally. It is interesting to note that the mGluR5 agonist CHPG induced PPE expression much stronger and more consistent than PPD expression [128] . This seems to echo an anatomical fact that the much denser distribution of mGluR5 receptors is seen in PPE-containing neurons [25, 27] . On the other hand, mGluR1 receptors that are preferentially expressed in PPD-containing neurons show a specific influence on dopamine-stimulated PPD expression (see below).
Pre-and postsynaptic mechanisms underlying the group I agonist-stimulated gene expression in vivo are not well understood due to limited data so far obtained from a rather complex in vivo animal model. According to available data, the group I agonist DHPG could stimulate striatal gene expression via presynaptically facilitated dopamine release. However, pharmacological blockade of dopamine D1 receptors did not affect ACPD-or DHPG-stimulated behaviors and IEG expression [123, 125] . Thus, the dopamine release, even though it is concomitantly evoked by the agonist, is not a critical component for orchestrating DHPG-induced gene expression. Besides dopamine, altered glutamate release could be another presynaptic element contributing to DHPG-induced gene expression. Infusion of ACPD at high concentrations or DHPG facilitated striatal glutamate release in conscious or anesthetized rats [91, [93] [94] [95] . It is possible that those agonists increase glutamate release that in turn interacts with postsynaptic group I mGluRs to alter gene expression. Additionally, the released glutamate can activate ionotropic glutamate receptors to regulate gene expression. However, in the recent attempts to evaluate the relative importance of ionotropic receptors in this scenario, we found that the NMDA and kainate/AMPA antagonists were ineffective in altering DHPG stimulation of motor activity [61] and gene expression [123] . This argues against the participation of the ionotropic receptors in the DHPG effects. Altogether, although group I stimulation is capable of facilitating dopamine and glutamate release, this presynaptic mechanism appears not to be significantly important for the group I-regulated gene expression.
In the light of predominant localization of group I mGluRs in postsynaptic projection neurons, exogenous DHPG should be able to directly interact with the postsynaptic receptors, resulting in gene expression. To establish an easily controlled model for postsynaptic neuronal study, primary cultures of striatal neurons were prepared from E19 rat embryos or neonatal 1-day-old rat pups [129] . In those dissociated neurons, ACPD and DHPG increased PPD and PPE mRNA expression [129] , confirming an efficient postsynaptic mechanism processing the strong genomic response.
Post-receptor signaling pathways bridging group I stimulation to DNA transcription were then investigated both in vivo and in vitro. According to the information gathered from signaling studies on striatal neurons or others, a biochemical cascade is hypothesized to transmit signals from surface group I receptors to nuclear gene expression. Activation of group I mGluRs increases the phospholipase C (PLC)-regulated PI hydrolysis which gives rise to diacylglycerol and inositol 1,4,5-trisphosphate (IP3 CRE), in the promoter region of opioid peptide DNAs in a sequence-specific manner. In experiments aimed to evaluate this cascade, we found that DHPG increased phosphorylation of CREB in striatal neurons in vivo [130] and in vitro [131] (Figs. 3 and 4) . Activation of mGluR5 rather than mGluR1 seems to mediate the DHPG phosphorylation of CREB since the mGluR5 antisense oligonucleotide or the mGluR5 antagonist MPEP, but not the mGluR1 antagonist 7-(hydroxyimino) cyclopropa [b]-chromen-1a-carboxylate ethyl ester (CPCCOet), blocked DHPG-or CHPG-stimulated CREB phosphorylation [131, 132] . The PLC inhibitor U73122 but not its inactive Fig. (3) . Increased CREB and Elk-1 phosphorylation in the striatum in vivo after an intracaudate injection of DHPG (500 nmol) in chronically cannulated rats (A) and in cultured striatal neurons in vitro after DHPG incubation at 100 µM for 10 min (B) detected using immunohistochemistry with specific anti-phospho antibodies. Striatal neuronal cultures were prepared from the E19 rat embryos or neonatal 1-day-old rat pups, and maintained in cultures for 18-20 days before use (122) . Both pCREB and pElk-1 immunoreactivity is concentrated within the nuclear compartment. C, fluorescent microscope images showing phenotypic characterizations of pCREB-and pElk-1-immunoreactive cells in cultured striatal neurons. Double immunofluorescent labeling was performed in cultures exposed to 100 µM of DHPG for 10 min. All pCREB-and pElk-1-positive cells are co-localized with a neuronspecific marker MAP2 and GABA, identifying pCREB-and pElk-1-containing cells as GABAergic neurons.
analogue U73343 blocked the CREB phosphorylation, indicating a crucial PLC activation step immediately downstream to the receptor activation [131] . With regard to the Ca 2+ signal, we found that DHPG induced a rapid and transient Ca 2+ release from the IP3-sensitive rather than ryanodine-sensitive Ca 2+ stores, and the released Ca sequentially triggered the opening of L-type voltage-operated Ca 2+ channels (VOCCs), resulting in a progressively larger Ca 2+ rise [131, 133] (Fig. 5) . It is the VOCC-mediated Ca 2+ rise that is largely responsible for subsequent CREB phosphorylation because the VOCC inhibitor nifedipine or verapamil prevented DHPG from inducing CREB phosphorylation [131] . At the protein kinase level, DHPG induced a concomitant phosphorylation of CaMKII and the CaMK inhibitor KN62 inhibited DHPG-induced CREB phosphorylation [134] . Thus, CaMK, likely CaMKII isotype, serves as a key substrate of Ca 2+ signals to increase CREB phosphorylation, as seen in many other cell lines or cultured neurons [135] [136] [137] . The results here largely support an above-proposed hypothesis that a group I mGluRregulated intracellular cascade (PLC-Ca 2+ -CaMK-CREB-CBP) exists in striatal neurons and effectively sends signals from the synapse to the nucleus. Besides CREB, another transcription factor has also been studied in this laboratory. Ternary complex factors (TCF), a subgroup of the ETS domain transcription factor family, dimerize with serum response factors (SRF) to assemble multiprotein complexes, binding to serum response element (SRE) on the promoter to regulate DNA transcription (for review, see [138] [139] [140] . Among the three members of TCFs, i.e., Elk-1 (p62TCF), SAP1, and SAP2/ERP/Net, Elk-1 is the first identified [141] and has drawn the most attention. Elk-1 can be rapidly phosphorylated on Ser 383 and Ser 389 in its C-terminal region by the extracellular signal-regulated kinases (ERK), a subgroup of the mitogen-activated protein (MAP) kinase family [142] . The phosphorylated Elk-1 increases its ability to form a ternary complex with SRF and SRE [143] , facilitating transcription of target DNAs [144] [145] . Robust Elk-1 phosphorylation was induced in the entire dorsal striatum in vivo following intracaudate injection of DHPG [130] or in most cultured striatal neurons following CHPG incubation [146] . Unlike pCREB induction, pElk-1 induction was not dependent on L-type VOCC activation [146] . Moreover, CHPG induced c-fos mRNA expression which was kinetically corresponded well to the Elk-1 phosphorylation and was attenuated by antisense oligonucleotides that selectively knocked down Elk-1 Fig. (4) . The mGluR5 agonist CHPG-stimulated CREB (A and B) and Elk-1 (C and D) phosphorylation in cultured striatal neurons after CHPG incubation at different concentrations for 10 min (A and C) or at different time points after the cessation of CHPG incubation at 1 mM (B and D) detected using Western blot. The quantified data are shown below the representative immunoblots and all bands were normalized as percentages of control values. Striatal neuronal cultures were prepared from the E19 rat embryos or neonatal 1-day-old rat pups, and maintained in cultures for 18-22 days before use. P < 0.05 vs. control.
proteins [146] . These results demonstrate a group I mGluRregulated Elk-1 phosphorylation which can facilitate gene expression. The mGluR5 agonist CHPG increased IP3-sensitive Ca 2+ release to effect Elk-1 phosphorylation [146] . DHPG also increased ERK1/2 phosphorylation [130] .
The diacylglycerol-dependent PKC pathway is another arm of the PI signaling pathway. PKC is among the protein kinases which are highly concentrated in medium spiny neurons, but not in glia [147] . MGluR stimulation in cultured striatal neurons caused a translocation of PKC from a cytoplasmatic (soluble) form, prevalent under resting conditions, to a membrane-bound form, a mode of activated PKC [148] , and concomitant IEG induction which was sensitive to PKC inhibitors [122] . The DHPG-induced CREB and Elk-1 phosphorylation in the striatum was blocked by pretreatment with the PKC inhibitor GF109203X [149] . The PKC activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) mimicked the stimulative effect of DHPG in vivo [149] and in vitro [150, 151] . These results demonstrate a PKC-sensitive pathway capable of upregulating transcription factor phosphorylation. Interestingly, the CaMK inhibitor KN62 or KN93 was able to block TPAinduced pCREB and pElk-1 expression [149, 150] . Thus, the PKC-sensitive pathway involves a downstream CaMK link to form a complete apparatus facilitating CREB and Elk-1 phosphorylation.
Taken together, striatal group I mGluRs regulate gene expression via both CREB and Elk-1 transcription factors. Multiple signaling pathways are involved in the transcription factor phosphorylation as summarized in Fig. 6 . It can be expected that complex interactions among these signaling elements exist at multiple levels [152] [153] [154] . Those interactions allow mGluRs to integrate genomic responses to cellular stimulation.
REGULATION OF DOPAMINE-DEPENDENT GENE EXPRESSION BY mGluRs
Cocaine and amphetamine stimulate striatal gene expression via a well-known D1/cAMP/protein kinase A (PKA) pathway. This pathway may need to cross-talk with group I mGluR-associated Ca 2+ /CaMK pathway to produce effective stimulation on gene expression. Co-expression of group I mGluRs and dopamine D1 receptors on the same striatal projection neurons [36] provides anatomical basis for the cross-talks. Two studies in rats found that blockade of mGluRs with MCPG attenuated acute amphetaminestimulated IEG (c-fos) and opioid peptide (PPD and PPE) mRNA expression in the striatum [155, 156] , indicating an mGluR dependency of dopamine-stimulated gene expression. The group I mGluRs may be responsible for this dependency because the group I agonist mimicked the stimulative effects of amphetamine on striatal IEG and opioid expression (see above). Moreover, amphetamine increased CaMKII phosphorylation and blockade of group I receptors attenuated amphetamine-stimulated phosphorylation of CaMKII, CREB, and Elk-1 [157, 158] . In mutant mice deficient of mGluR1 subtype, acute administration of amphetamine or a D1 agonist SKF 82958 produced significantly less PPD, but not PPE, mRNA induction as compared to that in the wildtype mice (Fig. 7) [71,72] . Thus, the mGluR1 regulation of dopamine-dependent gene expression is specific to PPD. This specific regulation seems to closely reflect the anatomical observation showing segregative expression of mGluR1 in PPD-containing striatonigral neurons [25] . The fact that group I mGluR activation contributes to the gene induction, but not to the motor stimulation (see above), in response to acute administration of amphetamine implies a preferential involvement of this group of mGluRs in the regulation of genomic responses. This supports a notion that, during synaptic stimulation, group I mGluRs function as the receptor to initiate intracellular responses that lead to gene expression and thus plasticity, but not the receptor to mediate fast synaptic signal transmission.
Little is known at present about the roles of group II/III mGluRs in the regulation of dopamine-dependent gene expression. Through the inhibition of adenylyl cyclase, group II/III receptors are expected to confine excitatory responses of the cAMP/PKA pathway to D1 stimulation and thus limit dopamine-stimulated gene expression. However, no attempt has been made to date to detect this issue, even though it is obviously valuable from a clinical point of view to develop therapeutic drugs for drug addiction by targeting those groups of mGluRs.
Overall, studies concerning the mGluRs regulation of both constitutive and dopamine-stimulated gene expression in striatal neurons are limited so far. Among numerous genes that could be inducible by stimulants, only two sets of genes, i.e., IEGs and opioid peptides, have been investigated in relation to mGluR activation. As to significance of these gene activities in mediating long-term drug effects, induced IEGs are probably involved in the facilitation of lateresponse genes, such as the opioid genes as described above. Opioid peptide induction may be more directly involved in resetting the responsiveness of striatal neurons to subsequent stimulant administration. It has been well documented that dynorphin suppresses, whereas enkephalin facilitates, chronic drug action after repeated exposures. For example, behavioral studies show that the dynorphin (κ) receptor agonists and enkephalin (δ) receptor antagonists attenuated, whereas the κ-antagonists and δ-agonists augmented, chronic behavioral activities (sensitization, reinforcement, rewarding effects, discriminative stimulus effects, etc.) induced by cocaine, amphetamine or morphine [159] [160] [161] . Overexpression of CREB and thus dynorphin in the nucleus accumbens decreased the rewarding behavior of cocaine [162] . These data support the assumption that mGluR1-sensitive dynorphin gene induction contributes to inhibition, whereas mGluR5-sensitive enkephalin gene induction, contributes to facilitation, of chronic drug action (Fig. 8) . Besides opioid genes, more studies are needed to explore the regulation of other potential gene expression in the forebrain by mGluRs, especially by group II/III subgroups, following acute as well as chronic drug administration. In general, inducible genes can be tentatively grouped into two sets of genes according to their potential functional roles: inhibitory vs. facilitatory sets of genes (Fig. 8) . Understanding of these genes' expression and functions and their relationship to mGluRs will provide invaluable information for neurobiology and treatment of drugs of abuse.
IONOTROPIC AND METABOTROPIC RECEPTOR INTERACTIONS
Ionotropic glutamate receptors, especially Ca 2+ -permeable NMDA subtype, are also actively involved in the regulation of gene expression. MGluRs may postsynaptically interact with ionotropic receptors to alter gene expression. NMDA and group I mGluRs are co-expressed in the medium-sized spiny projection neurons (see above), providing an anatomical basis for their functional interactions. Several recent studies indeed reveal an active interaction between ionotropic NMDA and group I mGluRs in various cellular activities. The group I, but not II, mGluR activation enhanced NMDA lesions of the rat striatum [163] and NMDA-stimulated GABA release from rat striatal slices [164] . Similarly, the group I agonist DHPG potentiated membrane depolarization and intracellular Ca 2+ levels in striatal neurons recorded from striatal slices [165] [166] [167] [168] . The DHPG potentiation was absent in striatal neurons from mGluR5, but not mGluR1, knockout mice, and blocked by an mGluR5, but not mGluR1, antagonist [168] . Recently, we found that DHPG at a sub-threshold dose augmented NMDA-induced CREB phosphorylation, which was blocked by an mGluR5 antagonist MPEP, but not by an mGluR1 antagonist CPCCOet [151] . Those studies indicate a facilitatory regulation of the NMDA receptor signals to intracellular activities by mGluR5 receptors. Interestingly, in exploring intracellular signaling pathway(s) mediating mGluR5 receptor signals to NMDA receptors, we found that the PKC inhibitors prevented DHPG from enhancing CREB phosphorylation induced by NMDA, and a low dose of a PKC activator mimicked the DHPG potentiation [151] . Thus, PKC is an important link of a signaling cascade Fig. (7) . Dark-field photomicrographs from emulsion-dipped slides illustrating the effects of an acute i.p. injection of saline or the D1 agonist SKF 82958 on basal levels of PPD (A) and PPE (B) mRNA expression in the striatum of mGluR1 knockout (-/-) and wild-type (+/+) mice. Mice were sacrificed 3 h after injection, and quantitative in situ hybridization was performed on 12 µm thick brain sections. Note that the induction of PPD mRNA in both the dorsal and ventral striatum of mutant mice was significantly less than that of wild-type mice in response to D1 stimulation (A). Such a difference was not found in PPE expression (B). Quantitative image analysis of PPD hybridization signals in the dorsal (C) and ventral (D) striatum was conducted in mutant and wild-type rats treated with i.p. injection of saline or amphetamine (AMPH) using the NIH imaging and expressed in terms of integrated density. *P < 0.05 vs. saline; and +P < 0.05 vs. mutant mice at the same dose.
transmitting mGluR5 receptor signals to NMDA receptors. Similar to the PKC role in processing the mGluR5/NMDA interaction to CREB phosphorylation, group I mGluRsensitive PKC is also identified as an essential link in a signaling pathway underlying the positive regulation of NMDA-or dopamine receptor-mediated responses in striatal [165, 167] or hippocampal [169] neurons. The molecular and functional changes in NMDA receptors via a group I mGluRregulated pathway are yet to be identified. A recent report shows that group I receptor stimulation increased [1] total expression levels of NMDA receptors, [2] fraction of functional NMDA receptors, and [3] NMDA receptor trafficking [170] .
In counterbalance with mGluR5, a negative fine tuner that could down-regulate NMDA responses may also exist to constitute a balancing apparatus to program a needed magnitude of NMDA responses to glutamate stimulation under different conditions. Group II and/or III mGluRs have been shown to suppress NMDA responses in many cases where group I mGluRs potentiated those responses [163, 164, 168] . Therefore, group II/III receptors are among good candidates to function as such a negative biological turner to balance their counterparts (group I mGluRs and others). Interestingly, mGluRs are found to primarily localize in the peripheral area of synapses as opposed to colocalized NMDA receptors in the core of synapses [171, 172] . Such an arrangement of the synaptic distribution of ionotropic and metabotropic receptors may substrate activation of these receptors by released glutamate at different strength, kinetics and sequence controlling interactions among these receptors.
MGluRs AS THERAPEUTIC TARGETS
MGluRs have been proposed to be novel targets for the development of therapeutic drugs for a variety of neurologic disorders, such as epilepsy, ischemia and several types of neurodegenerative diseases [173] [174] [175] . With regard to the neuropsychiatric disorders stemming from substance abuse mGluRs can also be worthwhile targets. Since the recent progress in the functional mGluR study has clearly indicated that mGluRs play an integral role in regulating striatal neuronal functions and, especially, gene expression in the presence of various abused substances (alcohol, morphine, nicotine and psychostimulants), the development of agents that interact with mGluRs could provide novel therapeutic tools for drug-related illnesses. For example, mGluR5 participates in the mediation of drug-induced gene expression that tends to facilitate chronic drug action. The development of agents that selectively block mGluR5 and thus facilitatory gene induction can then have a potential to abate chronic effects of drugs. On the other hand, mGluR1 mediates the induction of a different set of genes that tend to inhibit chronic drug action. Therefore, agents that increase mGluR1 activity can achieve a same effect as mGluR5 blockers in preventing drug abuse. Similarly, agents that can modify group II/III receptor activity can also be considered when the roles of these subtypes in the regulation of gene induction are investigated thoroughly. Besides their roles in gene expression, mGluRs are also known to be powerful presynaptic modulators for drug-stimulated dopamine and glutamate release. The modulation is subgroup-specific as the group I agonists facilitate, whereas the group II/III agonists suppress, the stimulated release of dopamine and glutamate. Therefore, agents that act presynaptically to modify mGluR subgroup activity can be designed to control the harmful excessive release of dopamine and/or glutamate. Ideally, agents with the power of inhibiting presynaptic group I mGluRs, if there is any, and activating group II/III mGluRs (group I antagonist with group II/III agonist activity) can be developed to maximally limit the stimulation of dopamine/glutamate release. There are clear advantages to target mGluRs rather than ionotropic glutamate receptors for the sake of medication. MGluRs, as the modulatory receptors in nature, have little impact on fast synaptic signal transmission. This is probably due to that mGluRs localize at the periphery of the postsynaptic membrane as opposed to the 'core' localization of ionotropic receptors in the synapse [171, 172] . Thus, mGluR agents should have minimal impact on normal synaptic function, which assures them to cause no general depression or cognitive side effects usually associated with the therapeutic use of the ionotropic glutamate receptor antagonists, especially in chronic therapy. Additionally, mGluR-targeted drugs should have no major peripheral adverse effects because mGluRs are not present in target organs of the autonomic nervous system. Along with rapid progresses in improving brain-blood barrier penetration, subtype specificity and other in vivo properties, mGluR agents would be expected to offer significant usefulness in clinical treatment of the disorders relevant to drugs of abuse in the future.
CONCLUSION
As an important element of glutamatergic transmission enriched in the striatal structure, mGluR activity is linked to many aspects of drug action. Initial studies reveal that mGluRs effectively modify the typical motor behaviors and transmitter release induced by cocaine or amphetamine. Recent experiments demonstrate an mGluR-sensitive stimulus-transcription coupling in striatal neurons that regulates immediate early gene and neuropeptide gene expression under normal and drug-treated conditions. The regulation of drug action by mGluRs is subtype-specific. Usually, a dual modulation of motor activity, transmitter release and gene expression exists in response to drug administration, depending upon mGluR subgroup involved. MGluR involvement in drug action suggests a novel avenue to develop effective therapeutic agents for drug abuse treatment by targeting at mGluRs. Since nuclear gene expression lies in heart of signal transduction, the development of small molecules that affect gene expression via influencing mGluR activity and associative signal transduction pathways represents a novel gene therapy approach to a variety of neurologic disorders induced by abused drugs. [83] Chiamulera, C., Epping-Jordan, M.P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., Conquet, F. 
